"Trodelvy gives new hope for triple-negative breast cancer"
By Son, Hyung-Min | translator Kang, Shin-Kook
24.07.23 05:40:06
가나다라
0
Dr. Aditya Bardia, Professor at UCLA, and Dr. Sohn, Joo Hyuk, Professor at Yonsei Cancer Hospital
ADC Trodelvy has improved PFS·OS·ORR in clinical trials, which were the basis for approval
"Unmet needs are high for triple-negative breast cancer treatment…Trodelvy will play a significant role"
Triple-negative breast cancer refers to a breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is a rare cancer that accounts for about 12-15% of all breast cancer. This cancer tends to be aggressive and has a high risk of metastasis and recurrence, leading to poor diagnosis.
However, patients with this type of cancer have relied on cytotoxic anticancer medicines, the first-generation cancer treatment. They were unable to benefit from the latest cancer treatments, such as antihormone therapies and targeted cancer therapies, because all the receptors that could be targeted were negative.
Trodelvy, a Tro
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)